The effect of anifrolumab on cutaneous lupus erythematosus characterized by the change of the inflammatory infiltrate analyzed by immunohistochemistry, spatial transcriptomics and single-cell RNA- and TCR-sequencing as well as on the clinical outcome - an open label, single arm phase IV pilot study

You may be able to join if

• Active lesions of histology proven cutaneous lupus erythematosus
• age18 years or older
• ability to understand and sign informed consent
• adequate contraception: females of childbearing potential must use 2 effective methods of avoiding pregnancy, one of which is a barrier method, from screening until 12 weeks after the final dose of investigational product unless the subject is surgically sterile (ie bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy).Sustained abstinence is an acceptable practice; however, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception
• Meets all of the following TB criteria: (a) No history of active TB prior to any Screening visit (b) No history of latent TB prior to initial Screening visit, with the exception of latent TB with documented completion of appropriate treatment Note: Subjects with no history of latent TB prior to the initial Screening visit, but who are diagnosed with latent TB during screening, may be considered eligible if appropriate treatment is initiated prior to randomisation. Such subjects may be re-screened if necessary to allow for local guidelines on latent TB treatment initiation.